Evidence map›Paper›PMID 39538371›Full record

ArticleCancer biology & therapy2024

Tripartite motif-containing protein 50 suppresses triple-negative breast cancer progression by regulating the epithelial-mesenchymal transition.

Danxiang Chen, Jing Jiang, Wei Zhang, Xinlin Li, Qidong Ge, Xia Liu, Xujun Li

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Danxiang ChenDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.
Jing JiangDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.
Wei ZhangDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.
Xinlin LiDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.
Qidong GeDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.
Xia LiuDepartment of Anesthesiology, Ningbo 1st Hospital, Ningbo, Zhejiang, China.
Xujun LiDepartment of Oncology, Ningbo No. 2 Hospital, Ningbo, Zhejiang, PR China.ORCID 0000-0002-8200-2995

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesTripartite motif-containing protein 50 (TRIM50) is a recently discovered E3 ubiquitin ligase that participates in tumor progression. TRIM50 is overexpressed in many cancers, although few studies focused on TRIM50's role in breast cancer.

methodsWe overexpressed TRIM50 in triple-negative breast cancer cell lines using plasmid and found that TRIM50 upregulation markedly reduced breast cancer cell proliferation, clone formation, and migration, as well as promoted breast cancer cell apoptosis. Western blotting revealed that accumulated TRIM50 resulted in both mRNA and protein depletion of SNAI1, and partially attenuated the epithelial-mesenchymal transition (EMT) induced by SNAI1.

resultsIn this study, we demonstrate that TRIM50 is downregulated in human breast cancer and that its overexpression closely correlates with diminished invasion capacity in breast cancer, suggesting that TRIM50 may serve as a diagnostic marker and therapeutic target.

conclusionTRIM50 plays a key role in breast cancer proliferation and potentially serves as a prognostic and therapeutic target.

Indexed as

Cell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionTripartite Motif ProteinsTriple Negative Breast NeoplasmsUbiquitin-Protein LigasesApoptosisCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansSnail Family Transcription FactorsSNAI1 protein, humanSnail Family Transcription FactorsTripartite Motif ProteinsUbiquitin-Protein LigasesbiomarkerEMTTRIM50triple-negative breast cancer

Identifiers

PMID39538371
PMCPMC11572070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.